As a central goal of PF Awareness Month and their ongoing work, the Pulmonary Fibrosis Foundation aims to improve diagnostic delays and misdiagnoses in this patient population.
A higher neutrophil count predicted worse disease course and higher long-term mortality in patients with systemic sclerosis-related interstitial lung disease.
Individuals with pulmonary fibrosis could develop more serious complications if infected with COVID-19, and those awaiting organ transplantation and other surgical interventions may face delays because of the pandemic.
Clinicians should use caution when interpreting the guidelines for the diagnosis and detection of sarcoidosis and must consider unique individual clinical circumstances when managing these patients.
Researchers characterized the safety and tolerability of nintedanib and the dose adjustments for adverse events in patients with systemic sclerosis-associated interstitial lung disease.
End-stage lung disease may significantly increase the risk for gastroesophageal reflux disease (GERD) in patients undergoing lung transplant without primary esophageal disease.
Treatment with nintedanib was associated with slowing the rate of forced vital capacity decline in patients with progressive fibrosing interstitial lung diseases.
Researchers investigated the incidence rates of interstitial lung disease in patients with rheumatoid arthritis receiving tofacitinib and identified potential risk factors.
In patients with COPD, lung methylation profiles differ according to the severity of airflow limitation and some epigenetic changes translate into specific gene expression changes in the lung.
When evaluating a patient with newly identified interstitial lung disease, using a questionnaire may help clinicians identify potentially relevant exposures for hypersensitivity pneumonitis.
